Senior Director, Strategic Therapeutic Area Lead, Autoantibody Pipeline, US Medical Affairs- Im

Overview

At Johnson & Johnson,we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and Med Tech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity.

Learn more at

Medical Affairs Group

Medical Affairs

People Leader

Horsham, Pennsylvania, United States of America

We are searching for outstanding talent to serve as Senior Director, Strategic Therapeutic Area Lead, Autoantibody Pipeline in our US Immunology Medical Affairs organization based in Horsham, PA
.

Our expertise in Innovative Medicine is informed and inspired by patients and healthcare professionals, whose insights fuel our science-based advancements. Visionaries like you work on teams that save lives by developing the medicines of tomorrow.

Our Immunology team leads in the development of transformational medicines for immunological disorders and illnesses. You can influence where medicine is going by restoring health to millions of people living with immune diseases.

Join us in developing treatments, finding cures, and pioneering the path from lab to life while championing patients every step of the way.

Learn more at

In this role, the candidate will be responsible for supervising a team of direct reports and serve as a leader of matrixed teams advancing the scientific strategy, pre-launch preparation, and planning for these indications within the Autoantibody Therapeutic Area (TA). Specific TA indication accountability and responsibilities will include pipeline indications such as Warm Autoimmune Hemolytic Anemia (WAiHA), and the Maternal Fetal Conditions of Hemolytic Disease of the Fetus and Newborn (HDFN), Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT), and other future non-neuroimmunology indications, and partner with other TALs to support other indications (such as gMG and Sjogren’s syndrome).

Universally, the strategic aims and ambition is to strive for Medical Affairs scientific leadership in relevant therapeutic areas, e.g. by identifying and addressing key stakeholders’ needs, and generating robust plans for data generation, data dissemination, and prelaunch and other initiatives supporting these indications, which may be the first approved therapy in these disease states.

Reporting to the VP of US Medical Affairs, Gastroenterology & Autoantibody
- Immunology this individual will be accountable for the execution and attainment of key medical objectives in compliant alignment with the business strategy and lead the team to deliver high-quality communications regarding the science and clinical applications of our products and/or the disease states to external stakeholders on a regional and national level. The ideal candidate will have a record of strong leadership combined with exceptional business acumen and clinical expertise as this individual is expected to build strong cross-functional relationships with internal colleagues as well as external relationships with HCPs.

• Leading a team of multiple AAb Medical Affairs team direct reports in developing a scientifically, strategically, and competitively strong strategy(s) around pre-launch support and related activities, including HCP and expert/opinion leader engagement, which are anticipated to require substantial effort in developing strategy for new indications which are anticipated to be First-in-Disease approved therapies.
• Lead the US MA AAb Pipeline Therapeutic Area team and matrixed team partners in developing sophisticated and innovative scientific strategies, data generation activities and subsequent tactics. Create opportunities for key talent to assume future leadership roles.
• Identify, prioritize, and oversee the implementation of innovative and compliant data dissemination approaches and data…